Gurnee, IL, United States of America

Cheol-Min Park

USPTO Granted Patents = 26 

 

 

Average Co-Inventor Count = 7.5

ph-index = 13

Forward Citations = 657(Granted Patents)


Location History:

  • Singapore, KR (2011)
  • Singapore, SG (2011 - 2014)
  • Gurnee, IL (US) (2003 - 2016)

Company Filing History:


Years Active: 2003-2016

Loading Chart...
Loading Chart...
Loading Chart...
26 patents (USPTO):Explore Patents

Title: The Innovative Journey of Cheol-Min Park: Pioneering Cancer Treatment

Introduction: Cheol-Min Park, based in Gurnee, Illinois, has made significant contributions to the field of pharmaceutical innovations, particularly in cancer treatment. With an impressive portfolio of 26 patents, his work revolves around the development of apoptosis-inducing agents that target anti-apoptotic Bcl-2 proteins, which play a crucial role in cancer progression and immune-related diseases.

Latest Patents: Among his notable patents, Cheol-Min Park has disclosed innovative compounds designed to inhibit the activity of anti-apoptotic Bcl-2 proteins. These patents detail compositions that contain these compounds and outline methods for effectively treating diseases where anti-apoptotic Bcl-2 proteins are expressed. His relentless pursuit of novel therapies showcases his dedication to advancing cancer treatment and addressing autoimmune diseases.

Career Highlights: Throughout his career, Cheol-Min Park has worked with renowned organizations, including Abbott Laboratories Corporation and AbbVie Inc. His experience in these companies has provided him with a robust platform to translate scientific research into practical applications. His extensive background enables him to remain at the forefront of pharmaceutical developments, constantly striving to improve patient outcomes.

Collaborations: Collaboration is vital in the realm of innovation, and Cheol-Min Park has worked alongside esteemed colleagues such as Steven Elmore and Aaron R. Kunzer. These partnerships have fostered a dynamic exchange of ideas and expertise, bolstering the research and development of cutting-edge therapies.

Conclusion: Cheol-Min Park's commitment to innovation and his impressive track record in patent development mark him as a significant figure in the fight against cancer and other immune diseases. His work not only contributes to scientific advancement but also holds the potential for impactful changes in clinical practice, ultimately benefiting countless patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…